Lee F Y, Workman P
Cancer Chemother Pharmacol. 1986;17(1):30-7. doi: 10.1007/BF00299862.
We have studied the effect of misonidazole (MISO) on the antitumour activity, normal tissue toxicity and pharmacokinetics of four bifunctional nitrogen mustards: chlorambucil (CHL); phenylacetic acid mustard (PAAM), a metabolite of CHL; beta, beta-difluorochlorambucil (beta-F2CHL), an analogue which is metabolized less efficiently by the beta-oxidation pathway; and melphalan (MEL). MISO (2.5 mmol/kg) increased the response of the KHT tumour to CHL, PAAM and beta-F2CHL by dose-modifying factors (DMFs) of 1.55-1.85, 1.35-1.65 and 1.5-1.8, respectively. In contrast, the activity of MEL was not altered. However, with 5.0 mmol/kg MISO an enhanced response to MEL was observed (DMF = 1.35-1.55). Similarly, for CHL and PAAM, but not MEL, acute toxicity was also increased by 2.5 mmol/kg MISO. The increase in toxicity with CHL and PAAM was similar to the increase in antitumour activity, and their therapeutic indices were unchanged. Effective chemosensitizers were shown to be powerful inhibitors of drug clearance. Thus, potent chemosensitizers such as MISO, the lipophilic analogue benznidazole (BENZO), the microsomal enzyme inhibitor SKF 525A, and the parent heterocycle imidazole all reduced the plasma clearance of CHL and its metabolites and therefore increased drug exposure (AUC). Conversely, the hydrophilic MISO metabolite Ro 05-9963 was a poor chemosensitizer and produced only very weak pharmacokinetic effects. As the DMFs for chemosensitization agreed very well with those for increased AUC, it seems likely that pharmacokinetic changes are the major cause of the enhancement of tumour response to CHL. For MEL, chemosensitization also appears to be related to pharmacokinetic changes. MISO at a dose of 2.5 mmol/kg produced no change in MEL pharmacokinetics and no enhancement of tumour response, whereas 5.0 mmol/kg MISO was effective on both counts.
我们研究了米索硝唑(MISO)对四种双功能氮芥的抗肿瘤活性、正常组织毒性和药代动力学的影响,这四种氮芥分别是:苯丁酸氮芥(CHL);苯乙酸氮芥(PAAM),它是CHL的一种代谢产物;β,β-二氟苯丁酸氮芥(β-F2CHL),一种通过β-氧化途径代谢效率较低的类似物;以及美法仑(MEL)。MISO(2.5 mmol/kg)分别使KHT肿瘤对CHL、PAAM和β-F2CHL的反应增加,剂量修正因子(DMF)分别为1.55 - 1.85、1.35 - 1.65和1.5 - 1.8。相比之下,MEL的活性未发生改变。然而,给予5.0 mmol/kg MISO时,观察到对MEL的反应增强(DMF = 1.35 - 1.55)。同样,对于CHL和PAAM,但不包括MEL,2.5 mmol/kg MISO也增加了急性毒性。CHL和PAAM毒性的增加与抗肿瘤活性的增加相似,它们的治疗指数未改变。有效的化学增敏剂被证明是药物清除的强力抑制剂。因此,强效化学增敏剂如MISO、亲脂性类似物苄硝唑(BENZO)、微粒体酶抑制剂SKF 525A以及母体杂环咪唑均降低了CHL及其代谢产物的血浆清除率,从而增加了药物暴露量(AUC)。相反,亲水性的MISO代谢产物Ro 05 - 9963是一种较差的化学增敏剂,仅产生非常微弱的药代动力学效应。由于化学增敏的DMF与AUC增加的DMF非常吻合,药代动力学变化似乎是肿瘤对CHL反应增强的主要原因。对于MEL,化学增敏似乎也与药代动力学变化有关。2.5 mmol/kg的MISO对MEL药代动力学无影响,也未增强肿瘤反应,而5.0 mmol/kg的MISO在这两方面均有效。